Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Fixed Sequence Study to Evaluate the Effect of Famotidine on the Pharmacokinetics and Safety of Taletrectinib in Healthy Adult Participant

NCT07742384 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT07742384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07742384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Fixed Sequence Study to Evaluate the Effect of Famotidine on the Pharmacokinetics and Safety of Taletrectinib in Healthy Adult Participant
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
February 2, 2027
Enrollment
56 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants